ArticleFrontiers in nutrition2025
Efficacy and safety of low-molecular-weight collagen peptides in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reframing Nutraceuticals in Knee Osteoarthritis with Sarcopenia: A Muscle-Joint-Centered Narrative Review.Nutrients · 2026Review
- Commentary: Efficacy and safety of low-molecular-weight collagen peptides in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial.Frontiers in nutrition · 2025Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Knee osteoarthritis (OA) is a common degenerative joint disease with limited safe, long-term treatment options. Nutritional interventions, such as low-molecular-weight collagen peptides (LMCP), have emerged as promising non-pharmacological strategies for joint health. However, clinical evidence is insufficient. Therefore, we aimed to assess the efficacy and safety of LMCP supplementation in patients with knee OA. Methods: In this double-blind, randomized, placebo-controlled trial, 80 adults aged 40-75 with Kellgren-Lawrence (KL) grade I or II OA received either 3,000 mg/day LMCP or a placebo for 180 days. Primary endpoint included changes in Western Ontario and McMaster Universities Osteoarthritis (WOMAC) pain scores. Secondary endpoints included visual analog scale (VAS), WOMAC physical function and total scores, joint space width (JSW), and inflammatory markers. Adverse events (AEs) and patient compliance were monitored throughout the study. Results: LMCP supplementation significantly reduced WOMAC pain compared to the placebo (-1.90 ± 4.14 vs. 0.61 ± 3.97; Conclusions: Daily supplementation of 3,000 mg of LMCP for 180 days was safe and effective in relieving joint pain and improving function in patients with KL grade I or II knee OA. LMCP is a promising nutrition-based non-pharmacological therapeutic option, particularly for individuals seeking complementary options to long-term non-steroidal anti-inflammatory drug therapy. Clinical trial registration: The trial was prospectively registered at the Clinical Research Information Service of South Korea (registration number: KCT0005507). The study was conducted at Pusan National University Korean Medicine Hospital (https://cris.nih.go.kr/).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.